ReviewPrzeglad gastroenterologiczny2026
Association between metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction.
Review in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with heart failure with preserved ejection fraction (HFpEF), driven by systemic inflammation, insulin resistance, and oxidative stress, which are shared pathophysiological mechanisms. HFpEF and MASLD often co-occur, especially in patients with conditions like obesity and type 2 diabetes mellitus (T2DM). The increasing global prevalence of both MASLD and HFpEF emphasises their shared risk factors and clinical implications. Early diagnosis and a multidisciplinary approach are important in the management of these interconnected diseases. Treatment strategies like the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have shown promise in addressing both conditions, improving liver steatosis, and reducing heart failure risk. Targeted therapies and lifestyle modifications are fundamental to managing MASLD and HFpEF, given their overlapping pathophysiology and impact on patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.